Obchod Lexicon - LXRX CFD
Pridať medzi obľúbené- Zhrnutie
- Historické dáta
- Udalosti
- Výkaz ziskov a strát
- Súvahový list
- Peňažný tok
- Vlastníctvo
Rozpätie | 0.05 | ||||||||
Nočný poplatok dlhej pozície
Long position overnight fee
Prejsť na platformu | -0.025457% | ||||||||
Nočný poplatok krátkej pozície
Short position overnight fee
Prejsť na platformu | 0.003235% | ||||||||
Nočný poplatok | 21:00 (UTC) | ||||||||
Minimálne množstvo na obchodovanie | 1 | ||||||||
Mena | USD | ||||||||
Marža | 20% | ||||||||
Burza cenných papierov | United States of America | ||||||||
Provízia pri predaji | 0% |
*Information provided by Capital.com
Lexicon Pharmaceuticals Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Predchádzajúce Zavrieť* | 2.68 |
Otvoriť* | 2.68 |
1-ročná zmena* | 54.02% |
Denný rozsah* | 2.65 - 2.75 |
Rozsah 52 týždňov | 1.31-3.79 |
Priemerný objem (10 dní) | 4.79M |
Priemerný objem (3 mesiace) | 29.14M |
Trhová kapitalizácia | 513.71M |
Pomer P/E | -100.00K |
Zdieľa mimoriadne | 189.56M |
Výnosy | 126.00K |
EPS | -0.63 |
Dividenda (udalosť %) | N/A |
Beta | 1.28 |
Ďalší dátum zárobku | Jul 31, 2023 |
Všetky údaje poskytuje spoločnosť Refinitiv, okrem údajov označených hviezdičkou, čo sú *údaje poskytnuté Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Zatvorenie | Change | Change (%) | Otvorenie | High | Low |
---|---|---|---|---|---|---|
Jun 2, 2023 | 2.72 | -0.03 | -1.09% | 2.75 | 2.77 | 2.64 |
Jun 1, 2023 | 2.68 | 0.00 | 0.00% | 2.68 | 2.70 | 2.54 |
May 31, 2023 | 3.27 | 0.39 | 13.54% | 2.88 | 3.39 | 2.87 |
May 30, 2023 | 2.86 | -0.52 | -15.38% | 3.38 | 3.43 | 2.65 |
May 26, 2023 | 3.14 | 0.12 | 3.97% | 3.02 | 3.20 | 2.90 |
May 25, 2023 | 2.86 | -0.17 | -5.61% | 3.03 | 3.03 | 2.83 |
May 24, 2023 | 2.98 | -0.04 | -1.32% | 3.02 | 3.02 | 2.94 |
May 23, 2023 | 3.02 | -0.16 | -5.03% | 3.18 | 3.27 | 3.02 |
May 22, 2023 | 3.17 | 0.10 | 3.26% | 3.07 | 3.27 | 3.03 |
May 19, 2023 | 2.97 | 0.04 | 1.37% | 2.93 | 3.00 | 2.86 |
May 18, 2023 | 2.86 | -0.04 | -1.38% | 2.90 | 2.91 | 2.76 |
May 17, 2023 | 2.89 | -0.04 | -1.37% | 2.93 | 2.94 | 2.84 |
May 16, 2023 | 2.90 | -0.03 | -1.02% | 2.93 | 2.95 | 2.81 |
May 15, 2023 | 2.94 | 0.06 | 2.08% | 2.88 | 3.01 | 2.84 |
May 12, 2023 | 2.83 | -0.29 | -9.29% | 3.12 | 3.16 | 2.81 |
May 11, 2023 | 3.10 | 0.06 | 1.97% | 3.04 | 3.17 | 2.98 |
May 10, 2023 | 3.03 | -0.13 | -4.11% | 3.16 | 3.16 | 2.91 |
May 9, 2023 | 3.00 | -0.24 | -7.41% | 3.24 | 3.24 | 2.96 |
May 8, 2023 | 3.23 | -0.27 | -7.71% | 3.50 | 3.53 | 3.20 |
May 5, 2023 | 3.45 | 0.36 | 11.65% | 3.09 | 3.75 | 3.05 |
Lexicon Events
Čas (UTC) (UTC) | Krajina | Udalosť |
---|---|---|
Monday, July 31, 2023 | ||
Čas (UTC) (UTC) 10:59 | Krajina US
| Udalosť Q2 2023 Lexicon Pharmaceuticals Inc Earnings Release Q2 2023 Lexicon Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
Tuesday, November 7, 2023 | ||
Čas (UTC) (UTC) 10:59 | Krajina US
| Udalosť Q3 2023 Lexicon Pharmaceuticals Inc Earnings Release Q3 2023 Lexicon Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Výročný
- Štvrťročne
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Celkové príjmy | 0.139 | 0.298 | 23.995 | 322.073 | 63.209 |
Výnosy | 0.139 | 0.298 | 23.995 | 322.073 | 63.209 |
Náklady na výnosy, celkom | 0 | 0 | 1.929 | 3.231 | 2.491 |
Hrubý zisk | 0.139 | 0.298 | 22.066 | 318.842 | 60.718 |
Celkové prevádzkové náklady | 100.899 | 87.388 | 70.792 | 180.628 | 166.488 |
Predaj/Všeobecné/Správca. Náklady, Celkom | 48.083 | 32.342 | 47.23 | 56.835 | 63.754 |
Výskum a vývoj | 52.816 | 55.046 | 153.621 | 91.924 | 100.243 |
Other Operating Expenses, Total | 0 | 0 | |||
Prevádzkový príjem | -100.76 | -87.09 | -46.797 | 141.445 | -103.279 |
Úrokový príjem (výdavky), čistý neprevádzkový | -2.78 | -0.802 | -14.544 | -20.676 | -20.777 |
Iné, Net | 1.596 | 0.134 | 2.767 | 3.35 | 3.508 |
Čistý príjem pred zdanením | -101.944 | -87.758 | -58.574 | 124.119 | -120.548 |
Čistý príjem po zdanení | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
Čistý príjem pred extra. Položky | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
Čistý príjem | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
Príjem k dispozícii bežnému Extra. Položky | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
Príjem k dispozícii bežnému vr. Extra. Položky | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
Zriedený čistý príjem | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
Zriedený vážený priemer akcií | 165.733 | 145.652 | 110.841 | 116.747 | 105.83 |
Zriedený EPS s výnimkou mimoriadnych položiek | -0.61511 | -0.60252 | -0.52845 | 1.11466 | -1.13907 |
Zriedený normalizovaný EPS | -0.61511 | -0.60252 | -1.71924 | 1.2741 | -1.13907 |
Celkom mimoriadne položky | 0 | ||||
Nezvyčajné výdavky (príjem) | 0 | 0 | -131.988 | 28.638 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Celkové príjmy | 0.024 | 0.028 | 0.039 | 0.035 | 0.037 |
Výnosy | 0.024 | 0.028 | 0.039 | 0.035 | 0.037 |
Náklady na výnosy, celkom | |||||
Hrubý zisk | |||||
Celkové prevádzkové náklady | 31.166 | 30.306 | 23.134 | 24.042 | 23.417 |
Predaj/Všeobecné/Správca. Náklady, Celkom | 19.14 | 16.329 | 12.577 | 10.686 | 8.491 |
Výskum a vývoj | 12.026 | 13.977 | 10.557 | 13.356 | 14.926 |
Prevádzkový príjem | -31.142 | -30.278 | -23.095 | -24.007 | -23.38 |
Úrokový príjem (výdavky), čistý neprevádzkový | -1.821 | -1.103 | -0.864 | -0.703 | -0.11 |
Iné, Net | 1.029 | 0.887 | 0.572 | 0.123 | 0.014 |
Čistý príjem pred zdanením | -31.934 | -30.494 | -23.387 | -24.587 | -23.476 |
Čistý príjem po zdanení | -31.934 | -30.494 | -23.387 | -24.587 | -23.476 |
Čistý príjem pred extra. Položky | -31.934 | -30.494 | -23.387 | -24.587 | -23.476 |
Čistý príjem | -31.934 | -30.494 | -23.387 | -24.587 | -23.476 |
Príjem k dispozícii bežnému Extra. Položky | -31.934 | -30.494 | -23.387 | -24.587 | -23.476 |
Príjem k dispozícii bežnému vr. Extra. Položky | -31.934 | -30.494 | -23.387 | -24.587 | -23.476 |
Zriedený čistý príjem | -31.934 | -30.494 | -23.387 | -24.587 | -23.476 |
Zriedený vážený priemer akcií | 189.014 | 188.98 | 174.904 | 149.616 | 149.15 |
Zriedený EPS s výnimkou mimoriadnych položiek | -0.16895 | -0.16136 | -0.13371 | -0.16433 | -0.1574 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Zriedený normalizovaný EPS | -0.16895 | -0.16136 | -0.13371 | -0.16433 | -0.1574 |
Nezvyčajné výdavky (príjem) | 0 |
- Výročný
- Štvrťročne
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Celkové aktíva | 140.866 | 88.921 | 157.719 | 337.754 | 173.324 |
Hotovosť a krátkodobé investície | 138.357 | 86.743 | 152.275 | 271.659 | 160.052 |
Hotovosť a ekvivalenty | 46.345 | 64.065 | 126.263 | 36.112 | 80.386 |
Krátkodobé investície | 92.012 | 22.678 | 26.012 | 235.547 | 79.666 |
Pohľadávky celkom, netto | 0.028 | 0.014 | 0.395 | 56.532 | 5.924 |
Accounts Receivable - Trade, Net | 0.028 | 0.014 | 0.395 | 56.532 | 5.924 |
Prepaid Expenses | 2.481 | 2.164 | 5.049 | 5.32 | 2.668 |
Total Assets | 194.299 | 136.909 | 203.788 | 417.715 | 284.136 |
Property/Plant/Equipment, Total - Net | 4.371 | 3.476 | 1.495 | 15.747 | 15.865 |
Property/Plant/Equipment, Total - Gross | 8.355 | 8.329 | 7.31 | 77.488 | 75.871 |
Accumulated Depreciation, Total | -3.984 | -4.853 | -5.815 | -61.741 | -60.006 |
Goodwill, Net | 44.543 | 44.543 | 44.543 | 44.543 | 44.543 |
Intangibles, Net | 0 | 19.716 | 50.119 | ||
Other Long Term Assets, Total | 4.519 | -0.031 | 0.031 | -0.045 | 0.285 |
Total Current Liabilities | 23.172 | 22.124 | 46.806 | 65.341 | 36.751 |
Accounts Payable | 10.395 | 9.152 | 5.469 | 12.178 | 17.759 |
Accrued Expenses | 12.373 | 10.469 | 29.691 | 42.151 | 14.482 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 11.646 | 11.012 | 1.115 | |
Other Current Liabilities, Total | 0.404 | 2.503 | 0 | 3.395 | |
Total Liabilities | 77.175 | 23.314 | 47.417 | 300.614 | 310.541 |
Total Long Term Debt | 48.579 | 0 | 0 | 234.171 | 243.887 |
Long Term Debt | 48.579 | 0 | 234.171 | 243.887 | |
Deferred Income Tax | 0 | 6.014 | |||
Other Liabilities, Total | 5.424 | 1.19 | 0.611 | 1.102 | 23.889 |
Total Equity | 117.124 | 113.595 | 156.371 | 117.101 | -26.405 |
Common Stock | 0.189 | 0.15 | 0.142 | 0.106 | 0.106 |
Additional Paid-In Capital | 1709.14 | 1608.75 | 1561.1 | 1462.17 | 1447.95 |
Retained Earnings (Accumulated Deficit) | -1589.72 | -1487.78 | -1400.02 | -1341.44 | -1471.58 |
Treasury Stock - Common | -2.061 | -7.518 | -4.843 | -3.817 | -2.876 |
Other Equity, Total | -0.428 | -0.01 | -0.006 | 0.084 | -0.012 |
Total Liabilities & Shareholders’ Equity | 194.299 | 136.909 | 203.788 | 417.715 | 284.136 |
Total Common Shares Outstanding | 188.726 | 148.917 | 141.496 | 106.272 | 105.926 |
Total Inventory | 0 | 4.243 | 4.68 | ||
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Celkové aktíva | 109.546 | 140.866 | 139.063 | 64.898 | 88.431 |
Hotovosť a krátkodobé investície | 105.937 | 138.357 | 136.203 | 61.968 | 86.502 |
Hotovosť a ekvivalenty | 26.001 | 46.345 | 18.834 | 21.45 | 59.52 |
Krátkodobé investície | 79.936 | 92.012 | 117.369 | 40.518 | 26.982 |
Pohľadávky celkom, netto | 0.261 | 0.028 | 0.039 | 0.034 | 0.037 |
Accounts Receivable - Trade, Net | 0.261 | 0.028 | 0.039 | 0.034 | 0.037 |
Prepaid Expenses | 3.348 | 2.481 | 2.821 | 2.896 | 1.892 |
Total Assets | 162.716 | 194.299 | 191.685 | 112.325 | 136.178 |
Property/Plant/Equipment, Total - Net | 8.607 | 4.371 | 8.032 | 2.835 | 3.242 |
Property/Plant/Equipment, Total - Gross | 6.303 | 8.355 | 6.109 | 6.105 | 6.104 |
Accumulated Depreciation, Total | -4.096 | -3.984 | -5.177 | -5.07 | -4.962 |
Goodwill, Net | 44.543 | 44.543 | 44.543 | 44.543 | 44.543 |
Other Long Term Assets, Total | 0.02 | 4.519 | 0.047 | 0.049 | -0.038 |
Total Current Liabilities | 20.371 | 23.172 | 18.445 | 16.862 | 18.905 |
Accounts Payable | 10.311 | 10.395 | 9.427 | 7.347 | 9.321 |
Accrued Expenses | 9.576 | 12.373 | 8.299 | 9.038 | 8.864 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | |||||
Total Liabilities | 74.67 | 77.175 | 47.667 | 41.495 | 43.48 |
Total Long Term Debt | 48.845 | 48.579 | 23.784 | 23.631 | 23.477 |
Other Liabilities, Total | 5.454 | 5.424 | 5.438 | 1.002 | 1.098 |
Total Equity | 88.046 | 117.124 | 144.018 | 70.83 | 92.698 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.19 | 0.189 | 0.189 | 0.15 | 0.15 |
Additional Paid-In Capital | 1712.56 | 1709.14 | 1705.61 | 1608.73 | 1605.9 |
Retained Earnings (Accumulated Deficit) | -1621.65 | -1589.72 | -1559.23 | -1535.84 | -1511.25 |
Treasury Stock - Common | -2.885 | -2.061 | -2.061 | -2.061 | -2.061 |
Other Equity, Total | -0.163 | -0.428 | -0.491 | -0.15 | -0.037 |
Total Liabilities & Shareholders’ Equity | 162.716 | 194.299 | 191.685 | 112.325 | 136.178 |
Total Common Shares Outstanding | 189.562 | 188.726 | 188.726 | 149.626 | 149.594 |
Other Current Liabilities, Total | 0.484 | 0.404 | 0.719 | 0.477 | 0.72 |
Long Term Debt | 48.845 | 48.579 | 23.784 | 23.631 | 23.477 |
- Výročný
- Štvrťročne
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Čistý príjem/Počiatočná čiara | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
Hotovosť z prevádzkovej činnosti | -88.851 | -87.017 | -142.969 | 113.807 | -148.607 |
Hotovosť z prevádzkovej činnosti | 0.427 | 0.292 | 2.934 | 3.654 | 3.683 |
Deferred Taxes | 0 | 0 | -6.014 | 0 | |
Bezhotovostné položky | 12.264 | 10.68 | -118.408 | 44.321 | 13.032 |
Úroky zaplatené v hotovosti | 2.289 | 0.799 | 17.353 | 19.211 | 16.465 |
Zmeny pracovného kapitálu | 0.402 | -10.231 | 31.079 | -58.287 | -44.774 |
Peniaze z investičných činností | -71.078 | 2.11 | 380.756 | -155.855 | 169.576 |
Kapitálové výdavky | -1.326 | -1.221 | -0.087 | -0.07 | -0.095 |
Ostatné investičné položky peňažných tokov, celkom | -69.752 | 3.331 | 380.843 | -155.785 | 169.671 |
Hotovosť z finančných činností | 142.209 | 22.709 | -147.636 | -2.226 | -2.244 |
Vydanie (vyradenie) zásob, netto | 93.341 | 34.409 | 68.944 | -0.941 | -0.24 |
Vydanie (vyradenie) dlhu, netto | 48.868 | -11.7 | -216.58 | -1.285 | -2.004 |
Čistá zmena v hotovosti | -17.72 | -62.198 | 90.151 | -44.274 | 18.725 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -31.934 | -101.944 | -71.45 | -48.063 | -23.476 |
Cash From Operating Activities | -31.613 | -88.851 | -67.282 | -47.843 | -23.421 |
Cash From Operating Activities | 0.112 | 0.427 | 0.324 | 0.216 | 0.109 |
Non-Cash Items | 3.68 | 12.264 | 8.648 | 5.783 | 2.797 |
Cash Interest Paid | 1.556 | 2.289 | 1.281 | 0.634 | 0.085 |
Changes in Working Capital | -3.471 | 0.402 | -4.804 | -5.779 | -2.851 |
Cash From Investing Activities | 12.093 | -71.078 | -95.252 | -18.056 | -4.408 |
Capital Expenditures | -0.248 | -1.326 | -0.08 | -0.076 | -0.076 |
Other Investing Cash Flow Items, Total | 12.341 | -69.752 | -95.172 | -17.98 | -4.332 |
Cash From Financing Activities | -0.824 | 142.209 | 117.303 | 23.284 | 23.284 |
Issuance (Retirement) of Stock, Net | -0.824 | 93.341 | 93.404 | -0.864 | -0.864 |
Issuance (Retirement) of Debt, Net | 0 | 48.868 | 23.899 | 24.148 | 24.148 |
Net Change in Cash | -20.344 | -17.72 | -45.231 | -42.615 | -4.545 |
Deferred Taxes |
Meno investora | Typ investora | Percento vynikajúce | Držané akcie | Zmena akcií | Dátum držby | Hodnotenie obratu |
---|---|---|---|---|---|---|
Artal International S.C.A. | Investment Advisor | 45.506 | 86262020 | 0 | 2023-03-31 | LOW |
BVF Partners L.P. | Hedge Fund | 8.5192 | 16149179 | 0 | 2023-03-31 | LOW |
Ulys, L.L.C. | Investment Advisor | 2.7979 | 5303814 | 0 | 2022-08-01 | |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.792 | 5292626 | 43032 | 2023-03-31 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 2.7644 | 5240247 | -11438 | 2023-03-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.6709 | 5062976 | -201281 | 2023-03-31 | LOW |
Invus Public Equities Advisors, LLC | Investment Advisor | 1.8549 | 3516214 | 0 | 2023-03-31 | LOW |
JP Morgan Asset Management | Investment Advisor | 1.6081 | 3048374 | 56229 | 2023-03-31 | LOW |
D. E. Shaw & Co., L.P. | Hedge Fund | 1.5515 | 2940997 | -136976 | 2023-03-31 | LOW |
New Enterprise Associates (NEA) | Venture Capital | 1.2567 | 2382286 | 0 | 2023-03-31 | LOW |
Pinnacle Associates Ltd. | Investment Advisor/Hedge Fund | 1.0235 | 1940224 | 7447 | 2023-03-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.9102 | 1725409 | 117468 | 2023-03-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.8251 | 1564098 | 47623 | 2023-03-31 | LOW |
Coats Lonnel | Individual Investor | 0.3927 | 744359 | 158356 | 2023-02-28 | LOW |
Fisher Investments | Investment Advisor/Hedge Fund | 0.38 | 720243 | 0 | 2023-03-31 | LOW |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.3794 | 719182 | 306384 | 2023-03-31 | LOW |
Charles Schwab Investment Management, Inc. | Investment Advisor | 0.3633 | 688611 | -7329 | 2023-03-31 | LOW |
Parkman Healthcare Partners LLC | Hedge Fund | 0.3563 | 675328 | 254126 | 2023-03-31 | HIGH |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.3561 | 675018 | -19915 | 2023-03-31 | LOW |
Asset Management One Co., Ltd. | Investment Advisor/Hedge Fund | 0.3194 | 605528 | 605528 | 2022-08-31 | LOW |
Prečo si vybrať Capital.com? Naše čísla hovoria samy za seba.
Capital.com Group535K+
Obchodníci
87K+
Aktívni klienti za mesia
$113M+
Mesačný objem investícií
$64M+
Výbery každý mesiac
Obchodná kalkulačka
Vypočítajte si svoj hypotetický zisk a stratu, ak ste otvorili obchod s CFD v určitý deň (vyberte dátum) a uzavreli v iný dátum (vyberte dátum).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Lexicon Company profile
O spoločnosti Lexicon
Lexicon Pharmaceuticals, Inc. je biofarmaceutická spoločnosť. Spoločnosť sa zameriava na objavovanie, vývoj a komercializáciu farmaceutických produktov na liečbu ľudských ochorení. Medzi jej pripravované lieky patria sotagliflozín, LX9211 a LX2761. Sotagliflozín je perorálne podávaná zlúčenina malých molekúl, ktorá sa vyvíja na liečbu srdcového zlyhania a cukrovky I. typu a cukrovky II. typu, srdcového zlyhania a chronického ochorenia obličiek. LX9211 je perorálne podávaná malá molekulová zlúčenina, ktorá sa vyvíja na liečbu neuropatickej bolesti. Spoločnosť vykonáva II. fázu klinického skúšania LX9211 pri diabetickej periférnej neuropatickej bolesti a druhú II. fázu klinického skúšania LX9211 pri postherpetickej neuralgii. LX2761 je perorálne podávaná zlúčenina malých molekúl, ktorá je navrhnutá tak, aby lokálne inhibovala sodíkovo-glukózový kotransportér 1 (SGLT1) v gastrointestinálnom trakte bez akejkoľvek inhibície sodíkovo-glukózového kotransportéra 2 (SGLT2) v obličkách.
Industry: | Bio Therapeutic Drugs |
8800 Technology Forest Place
8800 Technology Forest Place
77381
Výkaz ziskov a strát
- Annual
- Quarterly
Ľudia tiež sledujú
Stále hľadáte brokera, ktorému sa dá veriť?
Pridajte sa k 535 000 obchodníkom na celom svete, ktorí sa rozhodli obchodovať s Capital.com